Format

Send to

Choose Destination
Regen Med. 2018 Jan;13(1):29-39. doi: 10.2217/rme-2017-0121. Epub 2018 Jan 23.

Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK.

Author information

1
School of Social Sciences, Monash University, Clayton Campus, W414 Menzies Building, 20 Chancellors Walk, Melbourne, Australia.
2
Department of Sociology, Science & Technology Studies Unit, Wentworth College, University of York, York YO10 5DD, UK.
3
Cell & Gene Therapy Catapult, Guy's Hospital, 12th Floor Tower Wing, Great Maze Pond, London SE1 9RT, UK.

Abstract

This perspective paper examines the challenges of implementing regenerative medicine (RM) therapies within hospitals and clinics. Drawing on recent work in the social sciences, the paper highlights dynamics within existing healthcare systems that will present both hindrances and affordances for the implementation of new RM technologies within hospitals and clinics. The paper argues that identifying suitable locations for cell- and gene-therapy treatment centers requires an assessment of their institutional readiness for RM. Some provisional criteria for assessing institutional readiness are outlined, and the paper will suggest that it is necessary to begin developing a program for the phased introduction of RM in the longer term.

KEYWORDS:

GMP; National Health Service; commissioning; hospitals; institutional readiness; risk-sharing; technology adoption

PMID:
29360014
DOI:
10.2217/rme-2017-0121
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center